CoChat
Sign Up
Cited by 570Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies

The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Open access
Garassino, Marina Chiara, Cho, Byoung-Chul, Kim, Joo-Hang, Mazières, Julien, Vansteenkiste, Johan, Lena, Hervé, Corral Jaime, Jesus, Gray, Jhanelle E, Powderly, John, Chouaid, Christos, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Soo, Ross A, Huang, Yifan, Wadsworth, Catherine, Dennis, Phillip A, Rizvi, Naiyer A, Paz-Ares Rodriguez, Luis, Novello, Silvia, Hiret, Sandrine, Schmid, Peter, Laack, Eckart, Califano, Raffaele, Maemondo, Makoto, Kim, Sang-We, Chaft, Jamie, Vicente Baz, David, Berghmans, Thierry, Kim, Dong-Wan, Surmont, Veerle, Reck, Martin, Han, Ji-Youn, Holgado Martin, Esther, Belda Iniesta, Cristobal, Oe, Yuichiro, Chella, Antonio, Chopra, Akhil, Robinet, Gilles, Soto Parra, Hector, Thomas, Michael, Cheema, Parneet, Katakami, Nobuyuki, Su, Wu-Chou, Kim, Young-Chul, Wolf, Juergen, Lee, Jong-Seok, Saka, Hideo, Milella, Michele, Ramos Garcia, Inmaculada, Sibille, Anne, Yokoi, Takashi, Kang, Eun Joo, Atagi, Shinji, Spaeth-Schwalbe, Ernst, Nishio, Makoto, Imamura, Fumio, Gabrail, Nashat, Veillon, Remi, Derijcke, Sofie, Maeda, Tadashi, Zylla, Dylan, Kubiak, Kendra, Santoro, Armando, Uy, Ma. Noemi, Lucien Geater, Sarayut, Italiano, Antoine, Kowalski, Dariusz, Barlesi, Fabrice, Chen, Yuh-Min, Spigel, David, Chewaskulyong, Busyamas, Garcia Gomez, Ramon, Alvarez Alvarez, Rosa, Yang, Chih-Hsin, Hsia, Te-Chun, Denis, Fabrice, Sakai, Hiroshi, Vincent, Mark, Goto, Koichi, Bosch-Barrera, Joaquim, Weiss, Glen, Canon, Jean-Luc, Scholz, Christian, Aglietta, Massimo, Kemmotsu, Hirotsugu, Azuma, Koichi, Bradbury, Penelope, Feld, Ronald, Chachoua, Abraham, Jassem, Jacek, Juergens, Rosalyn, Palmero Sanchez, Ramon, Malcolm, Albert, Vrindavanam, Nandagopal, Kubota, Kaoru, Waller, Cornelius, Waterhouse, David, Coudert, Bruno, Mark, Zsuzsanna, Satouchi, Miyako, Chang, Gee-Chen, Herzmann, Christian, Chaudhry, Arvind, Giridharan, Selvaraj, Hesketh, Paul, Ikeda, Norihiko, Boccia, Ralph, Iannotti, Nichola, Haigentz, Missak, Reynolds, John, Querol, John, Nakagawa, Kazuhiko, Sugawara, Shunichi, Tan, Eng Huat, Hirashima, Tomonori, Gettinger, Scott, Kato, Terufumi, Takeda, Koji, Juan Vidal, Oscar, Mohn-Staudner, Andrea, Panwalkar, Amit, Daniel, Davey, Kobayashi, Kunihiko, Ladrera, Guia Elena Imelda, Schulte, Clemens, Sebastian, Martin, Cernovska, Marketa, Coupkova, Helena, Havel, Libor, Pauk, Norbert, Singh, Joginder, Murakami, Shuji, Csoszi, Tibor, Losonczy, Gyorgy, Price, Allan, Anderson, Ian, Iqbal, Mussawar, Torri, Vamsee, Juhasz, Erzsebet, Khanani, Saleem, Koubkova, Leona, Levy, Benjamin, Page, Ray, Bocskei, Csaba, Crinò, Lucio, Einspahr, David, Hagenstad, Christopher, Juat, Necy, Overton, Lindsay, Garrison, Mitchell, Szalai, Zsuzsanna·2018·The Lancet Oncology
DOI 10.1016/s1470-2045(18)30144-xPMC PMC7771363
Open this paper in CoChat — free account

Abstract

Background Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1.Methods ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423.Findings Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]). Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3. The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]). Immune-mediated events were manageable with standard treatment guidelines.Interpretation In patients with advanced and heavily pretreated NSCLC, the clinical activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents. Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.Funding AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30144-x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R. A., Huang, Y., Wadsworth, C., Dennis, P. A., Rizvi, N. A., Paz-Ares Rodriguez, L., Novello, S., Hiret, S., Schmid, P., Laack, E., Califano, R., Maemondo, M., Kim, S.-W., Chaft, J., Vicente Baz, D., Berghmans, T., Kim, D.-W., Surmont, V., Reck, M., Han, J.-Y., Holgado Martin, E., Belda Iniesta, C., Oe, Y., Chella, A., Chopra, A., Robinet, G., Soto Parra, H., Thomas, M., Cheema, P., Katakami, N., Su, W.-C., Kim, Y.-C., Wolf, J., Lee, J.-S., Saka, H., Milella, M., Ramos Garcia, I., Sibille, A., Yokoi, T., Kang, E. J., Atagi, S., Spaeth-Schwalbe, E., Nishio, M., Imamura, F., Gabrail, N., Veillon, R., Derijcke, S., Maeda, T., Zylla, D., Kubiak, K., Santoro, A., Uy, M. N., Lucien Geater, S., Italiano, A., Kowalski, D., Barlesi, F., Chen, Y.-M., Spigel, D., Chewaskulyong, B., Garcia Gomez, R., Alvarez Alvarez, R., Yang, C.-H., Hsia, T.-C., Denis, F., Sakai, H., Vincent, M., Goto, K., Bosch-Barrera, J., Weiss, G., Canon, J.-L., Scholz, C., Aglietta, M., Kemmotsu, H., Azuma, K., Bradbury, P., Feld, R., Chachoua, A., Jassem, J., Juergens, R., Palmero Sanchez, R., Malcolm, A., Vrindavanam, N., Kubota, K., Waller, C., Waterhouse, D., Coudert, B., Mark, Z., Satouchi, M., Chang, G.-C., Herzmann, C., Chaudhry, A., Giridharan, S., Hesketh, P., Ikeda, N., Boccia, R., Iannotti, N., Haigentz, M., Reynolds, J., Querol, J., Nakagawa, K., Sugawara, S., Tan, E. H., Hirashima, T., Gettinger, S., Kato, T., Takeda, K., Juan Vidal, O., Mohn-Staudner, A., Panwalkar, A., Daniel, D., Kobayashi, K., Ladrera, G. E. I., Schulte, C., Sebastian, M., Cernovska, M., Coupkova, H., Havel, L., Pauk, N., Singh, J., Murakami, S., Csoszi, T., Losonczy, G., Price, A., Anderson, I., Iqbal, M., Torri, V., Juhasz, E., Khanani, S., Koubkova, L., Levy, B., Page, R., Bocskei, C., Crinò, L., Einspahr, D., Hagenstad, C., Juat, N., Overton, L., Garrison, M., & Szalai, Z.
Affiliations
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Yonsei University (KR)
  • CHA University Bundang Medical Center (KR)
  • Université Toulouse III - Paul Sabatier (FR)
  • KU Leuven (BE)
  • Moffitt Cancer Center (US)
  • Carolina BioOncology Institute (US)
  • Inserm (FR)
  • Azienda Ospedaliera San Gerardo (IT)
  • Samsung Medical Center (KR)
  • National University Cancer Institute, Singapore (SG)
  • AstraZeneca (United States) (US)
  • AstraZeneca (United Kingdom) (GB)
  • Columbia University Irving Medical Center (US)
  • University of Turin (IT)
  • Institut de Cancérologie de l'Ouest (FR)
  • Imperial College London (GB)
  • Université Libre de Bruxelles (BE)
  • German Center for Lung Research (DE)
  • University of Palermo (IT)
  • Hospital Universitario Virgen del Rocío (ES)
  • University of Ottawa (CA)
Corresponding author
Garassino, Marina Chiara
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-04
Volume
19
Issue
4
Pages
521-536
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(18)30144-x
PMC
PMC7771363
OpenAlex
W2791290180
Cited by
568
References
29
Citations by year
2026: 15 · 2025: 30 · 2024: 55 · 2023: 61 · 2022: 85 · 2021: 96 · 2020: 92 · 2019: 85 · 2018: 47
FWCI
30.00
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
durvalumab, advanced non-small cell lung cancer, third-line therapy, PD-L1 expression, immune checkpoint inhibitors, EGFR mutation, ALK rearrangement, objective response rate, treatment safety, PD-L1 inhibitors, immune-related adverse events
MeSH terms
Antineoplastic Agents, Immunological, Injection Site Reaction, Anaplastic Lymphoma Kinase, Progression-Free Survival, Aged, Antibodies, Monoclonal, Aspartate Aminotransferases, Carcinoma, Non-Small-Cell Lung, Diarrhea, Fatigue, Female, gamma-Glutamyltransferase, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pneumonia, 4-Butyrolactone, B7-H1 Antigen, Response Evaluation Criteria in Solid Tumors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review